New Evidence NEJM Study

Rapid precision imaging could transform diagnosis of aldosterone driven hypertension.

27 November 2025

Comment from the Executive, Dr Manish Saxena, Hypertensions Specialist at Barts Health NHS Trust and Queen Mary University London who is lead investigator on studies with aldosterone synthase inhibitor commented –

“Hypertension remains the most important modifiable risk factor for CVD. Dysregulated aldosterone contributes to uncontrolled HTN, it is more widely prevalent than anticipated and is playing a big role in driving hypertension. Patients with primary aldosteronism need a clear diagnosis and could be amenable to surgical cure but current diagnostic techniques have certain limitations. This imaging technique and study results look very promising in identifying aldosterone secreting nodules, even ones that were missed on standard scans. It’s exciting to see researchers going for a bigger phase II study. If successful, it has the potential to change our clinical practice to help identify patients earlier and deliver more personalised medical care.” 

Read here

View Other News